WuXi Biologics Earns Coveted Spot on CDP’s Supplier Engagement A List, Strengthening Its Position as a Global ESG Leader
WuXi Biologics (2269.HK), a globally renowned Contract Research, Development, and Manufacturing Organization (CRDMO), has once again underscored its commitment to sustainability and climate action. The company announced that it has been named to the A List for Supplier Engagement Assessment (SEA) by CDP, a leading international non-profit that operates the world’s most comprehensive environmental disclosure system.
This achievement highlights WuXi Biologics’ leadership in driving climate-conscious practices across its supply chain and positions the company among a distinguished group of global corporations actively working to mitigate climate change risks. Inclusion on the CDP SEA A List is not only a marker of robust environmental stewardship but also a significant differentiator in a global business landscape where ESG (environmental, social, and governance) performance is increasingly influencing investor confidence, procurement decisions, and corporate reputation.
CDP’s Role and the Importance of Supplier Engagement
CDP—formerly known as the Carbon Disclosure Project—functions as the gold standard in environmental reporting. The organization’s rigorous assessment frameworks evaluate thousands of companies annually based on transparency, target-setting, risk management, governance, and overall performance in addressing climate-related challenges. Its Supplier Engagement Assessment specifically measures how effectively companies work with their suppliers to address emissions and climate risks across their value chains.
With supply chains responsible for an estimated 11.4 times more emissions than a company’s direct operations, supplier engagement has become a critical focus for businesses aiming to meet science-based climate goals and build long-term resilience. In 2024, CDP reported a record-high level of participation, with nearly 25,000 companies, representing approximately two-thirds of the global market capitalization, disclosing environmental data. Being named to the CDP SEA A List means that WuXi Biologics is in the top tier of this extensive network, demonstrating best-in-class performance on supplier engagement criteria.
WuXi Biologics: Advancing Climate Strategy Across the Value Chain
WuXi Biologics’ inclusion on the SEA A List is based on its exemplary work in four key areas: governance and business strategy, Scope 3 emissions disclosure, supplier target tracking, and risk management.
The company has established an integrated, science-aligned climate strategy anchored in the goals of the Science Based Targets initiative (SBTi). By focusing on both operational improvements and external engagement, WuXi Biologics aims to catalyze decarbonization across the entire value chain. In 2024 alone, the company achieved a 30% reduction in Scope 1 and Scope 2 greenhouse gas (GHG) emissions intensity compared to its 2020 baseline, marking significant progress toward its long-term ambition to reach net-zero emissions by 2050.
While these internal improvements are vital, the company’s real differentiator lies in how it partners with suppliers to amplify impact. Through structured supplier outreach programs, rigorous sustainability evaluations, and transparent Scope 3 reporting, WuXi Biologics actively supports its partners in setting and achieving their own climate goals. Supplier performance is continuously monitored and integrated into broader ESG assessments, which helps ensure that all stakeholders are aligned on climate accountability.
CEO’s Perspective on the Recognition
Commenting on the honor, Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the company’s ESG Committee, stated:
“We are very pleased to be named to the CDP’s A List for its Supplier Engagement Assessment—an acknowledgement that further inspires our steadfast dedication to driving sustainability. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to promote responsible practices.”
Dr. Chen’s remarks reflect WuXi Biologics’ broader vision to not only meet environmental compliance standards but also drive meaningful progress across the biopharmaceutical industry. The company’s CRDMO model plays a critical role in supporting innovation across global health systems, and this recognition signals its leadership in delivering those services sustainably.
Recognition Beyond the CDP A List: A Broad ESG Footprint
WuXi Biologics’ inclusion on the CDP SEA A List is just one among many accolades that the company has earned in recent years, validating its ESG strategy from multiple vantage points. The company has amassed a portfolio of top-tier sustainability recognitions from some of the most respected ESG rating agencies and initiatives worldwide:
- CDP Water Security A List: Recognized for excellence in managing water-related environmental impacts and for adopting best practices to reduce water usage and mitigate water risks in operations.
- CDP Climate Change Leadership-Level Score (A-): Received for two consecutive years, this score reflects the company’s strong climate governance, target-setting, and emissions reduction efforts.
- MSCI ESG Rating: AAA: This top rating positions WuXi Biologics among the elite performers in its industry group, signaling low exposure to ESG risks and strong risk management practices.
- EcoVadis Platinum Medal: Places WuXi Biologics in the top 1% of over 130,000 companies evaluated globally, reflecting its leadership across labor practices, ethics, environment, and sustainable procurement.
- Dow Jones Sustainability Indices (DJSI): Selected for inclusion in this globally respected benchmark for corporate sustainability performance.
- Sustainalytics ESG Risk Rating: Given the highest “negligible-risk” rating by Sustainalytics and ranked as an ESG top-rated company in both industry and regional categories for five consecutive years.
- FTSE4Good Index Series Constituent: Demonstrates compliance with globally recognized ESG standards, making the company a preferred choice for sustainability-minded investors.
- Hang Seng ESG 50 Index: Inclusion in this index reflects the company’s standing among the top ESG performers in the Hong Kong market.
- ISS ESG Prime Rating: Indicates that the company meets ambitious performance thresholds defined by leading ESG research firm Institutional Shareholder Services.
Alignment with Global Sustainability Frameworks
WuXi Biologics is not only focused on performance metrics but also deeply committed to aligning its strategy with global frameworks and coalitions that shape the sustainability agenda. It is a proud participant of the United Nations Global Compact (UNGC), the world’s largest corporate sustainability initiative, and the Pharmaceutical Supply Chain Initiative (PSCI), a collaboration of pharmaceutical companies promoting responsible supply chain practices.
These memberships emphasize the company’s proactive approach to embedding sustainability into every facet of its operations—from ethical sourcing and supplier audits to emissions reductions and waste minimization.
Driving ESG in the Biopharma Sector
As a global CRDMO, WuXi Biologics occupies a central position in the biopharmaceutical innovation ecosystem, enabling biotechs and pharma companies to accelerate development timelines and bring novel therapies to market. The company’s commitment to sustainability enhances the impact of this ecosystem, ensuring that innovation is not pursued at the expense of environmental integrity.
In a sector where energy-intensive manufacturing processes and complex logistics networks are often the norm, WuXi Biologics distinguishes itself by making green manufacturing and low-carbon supply chain management strategic priorities. The company’s “Green CRDMO” concept exemplifies how it blends operational excellence with climate responsibility, offering partners and clients a compelling value proposition that meets both business and environmental objectives.
Scaling Sustainability Ambitions
Looking forward, WuXi Biologics continues to invest in technologies and frameworks that will enable it to meet its 2050 net-zero target. These investments include:
- Expansion of renewable energy use across global facilities
- Increased use of energy-efficient equipment and green building certifications
- Digital solutions for real-time emissions monitoring
- Supplier capacity building programs to align upstream emissions with SBTi-aligned targets
- Transparent ESG disclosures to maintain credibility with stakeholders and ensure regulatory readiness
The company’s ability to simultaneously deliver cutting-edge biologics development and manufacturing services while advancing a robust climate strategy positions it at the forefront of next-generation, sustainability-first biomanufacturing.
WuXi Biologics’ naming to the CDP Supplier Engagement A List in 2024 is a powerful validation of its leadership in sustainable supply chain practices and climate risk management. The recognition is not an isolated milestone but part of a much broader commitment to driving ESG excellence across the biopharmaceutical value chain.
With a growing list of sustainability accolades, participation in leading global initiatives, and clear, measurable climate goals, WuXi Biologics is setting a new benchmark for environmental responsibility in the life sciences sector. As the global economy accelerates its shift toward decarbonization and responsible innovation, WuXi Biologics stands well-prepared to lead—not only as a service provider, but as a steward of climate action and corporate sustainability.
CDP is a global non-profit that runs the world’s only independent environmental disclosure system. As the founder of environmental reporting, the organization believes in transparency and the power of data to drive change. Partnering with leaders in enterprise, capital, policy and science, CDP surfaces the information needed to enable Earth-positive decisions. It helped more than 24,800 companies and 1,100 cities, states and regions disclose their environmental impacts in 2024.
Financial institutions with more than a quarter of the world’s institutional assets use CDP data to help inform investment and lending decisions. Aligned with the ISSB’s climate standard, IFRS S2, as its foundational baseline, CDP integrates best-practice reporting standards and frameworks in one place. The team is truly global, united by a shared desire to build a world where people, planet and profit are truly balanced.
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
